Or in the case of COVID-19…..the vaccine or COVID-19
Writer at Independent ….mRNA Fraud - Regulatory and Manufacturing Investigations
Jul. 6, 2022, 12:00 p.m.
Journalist Article
“Finding 4: There are two separate Investigational New Drug numbers for mRNA-1273: one held by Moderna, the other – by DMID (NIH), representing a serious conflict of interest.
Moderna’s documents state that “A letter from DMID [Division of Microbiology and Infectious Diseases at NIH] authorizing the US Food and Drug Administration (FDA) to refer to IND#19635 to support review of this IND [Moderna’s own IND# 19745] is provided in Module 1.4” (module is not included in the HHS package of documents).
The FDA’s January 30, 2022 “Summary Basis for Regulatory Action SPIKEVAX” document[9] reveals the following timeline for Moderna’s product:
According to this timeline the product has two sponsors/owners (holders of the Investigational New Drug application[10] packages), one of whom is the NIH’s division organizationally reporting to Anthony Fauci. The date of the pre-IND meeting for SPIKEVAX is February 19, 2020, the IND submission for NIH IND is the following day, February 20, while Moderna’s own IND was submitted on April 27, 2020. To recall, according to the CDC, as of January 11, 2020 Chinese health authorities said they’ve identified more than 40 human infections as part of this outbreak that was first reported on December 31. The World Health Organization announced the preliminary identification of the novel coronavirus on January 9. The record of Wuhan-Hu-1 includes sequence data, annotation and metadata from this virus isolated from a patient approximately two weeks prior.
This raises several questions that warrant further investigation:
How was it possible for the NIH/Moderna to have the pre-IND meeting for a Phase 1 human clinical trial scheduled with the FDA for a vaccine product a month before the covid pandemic was declared? Preparation for a pre-IND meeting is typically a several months long, expensive and labor consuming process.
How was it possible to have all materials prepared and the entire non-clinical testing process completed for this specific product related to a very specific virus which was only isolated and sequenced (so we were told) by January 9, 2020?
What is the precise commercial and legal arrangement between Moderna and NIH regarding SPIKEVAX? Ownership of the IND is both legal and commercial matter, which in the case of public-private partnership must be transparently disclosed.
Does NIH financially benefit from sales of Moderna product? Who at NIH specifically?
Does forcing vaccination with the Moderna product via mandates, government funded media campaigns and perverse government financial incentives to schools, healthcare system and employers represent a significant conflict of interest for the NIH as a financial beneficiary of these actions?
Does concealing important safety information (see Section 6) by a financially interested party (NIH and Moderna) represent a conspiracy by the pharma-government cartel do defraud the public?
Additionally, it is interesting to note that immediately after the pre-IND meeting with the FDA, an extremely heavy volume of orders for Moderna stock began to be placed in the public markets. It would warrant an additional investigation into the investors that were able to predict the spectacular future of the previously poorly performing stock with such timely precision. “
Clearly, and without any doubt, the CHICKEN came first.
I really like this journalists approach and diligence. TY Viking for passing it along.
This looks like the kinds of info that will find its way into a criminal proceeding.